IN THE NEWS
Cystic Fibrosis News Today, September 2017
CF News Today, September 2017
Bio IT World, September 2017
Xconomy, November 2015
EXOTECT is focused on developing a rational approach towards discovery of therapeutic candidates for asthmatics and patients of other respiratory diseases where mucus overproduction is a feature.
Asthma and COPD can be controlled with proper therapeutic interventions but there are still 5-10% of patients that remain refractory. Refractory patients accounted for nearly 25,000 deaths in just asthma alone. Currently the global asthma market is expected to reach 23.1 billion by 2023. However, treatment regiments are still poor for those with refractory disease. Currently, the market is dominated by corticosteroids and bronchodilators that treat symptoms rather than the underlying cause. The prescription of a handful of drugs and the prevalence of refractory patients highlights the need for new therapeutic interventions. Mucus hyperproduction in asthma is an important component of the mortality and morbidity related to this disease. An effective therapy for this is an urgent clinical need. As of now, no effective therapies exist that tackles this aspect of asthma, despite significant advances in management of other aspects of the disease like airway hyperreactivity and inflammation.Dr. Burton Dickey’s research into mucus hyperproduction has identified a druggable target in the mucus production pathway, Synaptotagmin. These synaptotagminsare located on synaptic vesicles or secretory granules. Dr. Dickey has shown dramatic decrease in mucus production in animals which do not have a functional synaptotagmins.Exotect, LLC is focused on developing a rational approach towards discovery of therapeutic candidates to reduce synaptotagminsaction in asthmatics and patients of other respiratory diseases where mucus overproduction is a feature.
A combinationof high throughput screeningand molecular modeling is being used to identifycandidates for further hit-to-lead optimization.
An effective management of mucus hypersecretion will be useful for the following markets:
1.Asthma: 9% of Americans have asthma; Costs ~$56 billion in medical costs, lost school and work, and early death;
2.Chronic Obstructive Pulmonary Disease (COPD): 3rd leading cause of death in Americans; 12.7 million people are currently living with this disease; Costs nearly $50 billion in direct and indirect costs
3.Cystic Fibrosis: Most common lethal genetic disease in the US; 30,000 people are currently living with the disease and 1,000 new cases diagnosed annually